Serious infections and cardiovascular complications among patients with chronic lymphocytic lymphoma treated with first-line ibrutinib or bendamustine/rituximab.

被引：0
|
作者：
Irwin, Debra E.
Thompson, Stephen
Ribalov, Rinat
Choudhry, Azhar
机构：
[1] IBM Watson Hlth, Cambridge, MA USA
[2] Teva Pharmaceut Inc, Parsippany, NJ USA
[3] Teva Pharmaceut Ind LTD, Petah Tiqwa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19503
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world incidence and costs of serious infections and cardiovascular complications among patients with indolent non-Hodgkin lymphoma treated with first-line ibrutinib or bendamustine/rituximab.
    Irwin, Debra E.
    Thompson, Stephen
    Ribalov, Rinat
    Choudhry, Azhar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] First-line Therapy for Patients with Chronic Lymphocytic Leukemia Ibrutinib showed PFS Benefit over Bendamustine Rituximab
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 153 - 153
  • [3] Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia
    Irwin, Debra
    Szabo, Erika
    Pathak, Ashutosh
    Tang, Boxiong
    BLOOD, 2017, 130
  • [4] Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra
    Wilson, Kathleen
    Thompson, Stephen
    Choudhry, Azhar
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 623 - 628
  • [5] ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Lachaine, J.
    Kouroukis, C. T.
    VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
  • [6] Provider Perceptions of Shine and Ibrutinib, Bendamustine, and Rituximab in the First-Line Setting
    Baird, Samuel C.
    Bone, Robert N.
    Jeune-Smith, Yolaine
    Feinberg, Bruce A.
    Baljevic, Muhamed
    BLOOD, 2022, 140 : 13234 - 13235
  • [7] Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab
    Spacek, Martin
    Obrtlikova, Petra
    Hrobkova, Stanislava
    Cmunt, Eduard
    Karban, Josef
    Molinsky, Jan
    Simkovic, Martin
    Mocikova, Heidi
    Mohammadova, Lekaa
    Panovska, Anna
    Novak, Jan
    Trneny, Marek
    Smolej, Lukas
    Doubek, Michael
    LEUKEMIA RESEARCH, 2019, 79 : 17 - 21
  • [8] High Risk of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated With First-line Bendamustine Rituximab and Rituximab Maintenance
    Rangel-Patino, Juan
    Kridel, Robert
    Kuruvilla, John
    Prica, Anca
    Kukreti, Vishal
    Bhella, Sita
    Delabie, Jan
    Vijenthira, Abi
    Crump, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S503 - S503
  • [9] Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation
    Fradley, Michael
    Lafeuille, Marie-Helene
    Emond, Bruno
    Crawford, Samuel
    Chen, Naijun
    Volodarsky, Raisa
    Nielsen, Jacqueline
    Srivastava, Bhavini Patel
    BLOOD, 2022, 140 : 10983 - 10984
  • [10] Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) : 3 - 19
12345